Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotigalimab in Recurrent Ovarian Cancer
NCT05201001Phase 2Withdrawn
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Sep 2023
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sotigalimab in ovarian cancer, sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Planned start Sep 2023; status: withdrawn.
02
Drugs
sotigalimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05201001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201001.